Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

被引：0
|
作者：
Sheila Seleri Assunção
Reisa A. Sperling
Craig Ritchie
Diana R. Kerwin
Paul S. Aisen
Claire Lansdall
Alireza Atri
Jeffrey Cummings
机构：
[1] US Medical Affairs – Neuroscience,Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences
[2] Genentech,Department of Neurology and Neurotherapeutics
[3] A Member of the Roche Group,Center for Brain/Mind Medicine, Department of Neurology
[4] Brigham and Women’s Hospital,Chambers
[5] Massachusetts General Hospital,Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences
[6] Harvard Medical School,undefined
[7] University of Edinburgh,undefined
[8] Kerwin Medical Center,undefined
[9] University of Texas Southwestern Medical Center,undefined
[10] University of Southern California Alzheimer’s Therapeutic Research Institute,undefined
[11] F. Hoffmann-La Roche,undefined
[12] Banner Sun Health Research Institute,undefined
[13] Brigham and Women’s Hospital,undefined
[14] Harvard Medical School,undefined
[15] University of Nevada,undefined
来源：
Alzheimer's Research & Therapy | / 14卷
关键词：
Alzheimer’s disease; Clinical trials; Clinical meaningfulness; Meaningful benefit; Biomarkers; Preclinical; Mild cognitive impairment due to Alzheimer’s disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [11] Challenges in demonstrating the value of disease-modifying therapies for Alzheimer's disease
    Gustavsson, Anders
    Pemberton-Ross, Peter
    Montero, Melissa Gomez
    Hashim, Mahmoud
    Thompson, Robin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (06) : 563 - 570
  • [12] Clinical Management in Alzheimer's Disease in the Era of Disease-Modifying Therapies
    Guo, Michael H.
    Vaishnavi, Sanjeev N.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2023, 25 (05) : 121 - 133
  • [13] Clinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
    Michael H. Guo
    Sanjeev N. Vaishnavi
    Current Treatment Options in Neurology, 2023, 25 : 121 - 133
  • [14] Setbacks and Opportunities in Disease-Modifying Therapies in Alzheimer Disease
    Forester, Brent P.
    Patrick, Regan E.
    Harper, David G.
    JAMA PSYCHIATRY, 2020, 77 (01) : 7 - 8
  • [15] Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease
    Evans, Jonathan R.
    Barker, Roger A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (08) : 1249 - 1258
  • [16] Evaluating Disease-Modifying Agents: A Simulation Framework for Alzheimer's Disease
    Guo, Shien
    Getsios, Denis
    Revankar, Nikhil
    Xu, Peng
    Thompson, Gwilym
    Bobula, Joel
    Lacey, Loretto
    Gaudig, Maren
    PHARMACOECONOMICS, 2014, 32 (11) : 1129 - 1139
  • [17] Evaluating Disease-Modifying Agents: A Simulation Framework for Alzheimer’s Disease
    Shien Guo
    Denis Getsios
    Nikhil Revankar
    Peng Xu
    Gwilym Thompson
    Joel Bobula
    Loretto Lacey
    Maren Gaudig
    PharmacoEconomics, 2014, 32 : 1129 - 1139
  • [18] Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives
    Imbimbo, Bruno P.
    Lozupone, Madia
    Watling, Mark
    Panza, Francesco
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (09) : 919 - 933
  • [19] Molecular Pathogenesis and Disease-modifying Therapies of Alzheimer's Disease and Related Disorders
    Iwatsubo, Takeshi
    JMA JOURNAL, 2022, 5 (03): : 307 - 313
  • [20] Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
    Todd E. Golde
    Neurotherapeutics, 2022, 19 : 209 - 227
12345